Answers are grounded in this paper and cite their sources.
Artificial Intelligence (AI) is revolutionizing the pharmaceutical industry by accelerating drug discovery, enhancing the efficiency of clinical trials, and enabling the development of personalized medicine.It is also being used in pharmaceutical regulatory affairs to automate the regulatory filling and document management.This review highlights the current applications of AI in drug development and pharmaceutical regulatory affairs, explores key case studies and technological advancements, and discusses the challenges and regulatory considerations associated with these applications.As the AI drug discovery market is growing significantly [1], understanding its integration within pharmaceutical pipelines is critical for stakeholders across industry and academia.
No takes yet. Share an insight, caveat, or question.
Rumel Dey (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: